EGFR and non-small cell lung carcinoma: We also studied the molecular mechanism and showed that Kremen2 bound to SOCS3 to inhibit SOCS3-mediated EGFR degradation and promote activation of the EGFR signaling pathway, which exacerbated the malignant progression of NSCLC (Fig. 7).